Cancer drug developer Endocyte extends series C, reins in $26m | AltAssets Private Equity News

Subscribe today

Advanced
Search

Cancer drug developer Endocyte extends series C, reins in $26m

19 Oct 2009

Endocyte Inc, a cancer drug discovery and development company, has closed a $26m extension of its series C financing round.

Sorry, to read the full story you must be a Premium Subscriber

Are you a subscriber?

In order to view premium content you need to be a Premium Subscriber. You can subscribe now to access premium online content.

Become a Premium Subscriber
for only £150 / €180 / $225 p.a.

Login area

If you are already a AltAssets subscriber please log in below.